Quest Diagnostics Incorporated
235.46USD
-0.0400 (-0.02%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $2.86▲ | $2.8 | 11 | 1 |
| Next quarter | $2.68▲ | $2.61 | 11 | 1 |
| Current year | $11.19▲ | $10.77 | 15 | 0 |
| Next year | $12.06▲ | $11.67 | 16 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.82 | $3.12 | +0.30 (+10.5%) |
| 2026-03-31 | $2.37 | $2.5 | +0.13 (+5.6%) |
| 2025-12-31 | $2.36 | $2.42 | +0.06 (+2.6%) |
| 2025-09-30 | $2.5 | $2.6 | +0.10 (+3.9%) |
256 ratings from 32 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Maintained | Neutral | $232 $245 | Sep 8, 2026 |
| JP Morgan | Maintained | Neutral | $220 $250 | Jul 28, 2026 |
| UBS | Maintained | Neutral | $220 $232 | Jul 25, 2026 |
| Mizuho | Maintained | Outperform | $235 $260 | Jul 24, 2026 |
| Truist Securities | Maintained | Hold | $225 $250 | Jul 24, 2026 |
| Barclays | Maintained | Overweight | $230 $250 | Jul 24, 2026 |
| Baird | Maintained | Neutral | $236 $255 | Jul 24, 2026 |
| Baird | Maintained | Neutral | $232 $236 | Jul 13, 2026 |
| UBS | Maintained | Neutral | $210 $220 | Apr 22, 2026 |
| Baird | Maintained | Neutral | $224 $229 | Apr 22, 2026 |
| Barclays | Maintained | Overweight | $225 $230 | Apr 22, 2026 |
| Truist Securities | Maintained | Hold | $220 $225 | Apr 22, 2026 |
| Evercore ISI Group | Maintained | In-Line | $220 $210 | Apr 8, 2026 |
| Mizuho | Maintained | Outperform | $210 $235 | Feb 12, 2026 |
| Truist Securities | Maintained | Hold | $205 $220 | Feb 11, 2026 |
| UBS | Maintained | Neutral | $190 $210 | Feb 11, 2026 |
| Evercore ISI Group | Maintained | In-Line | $190 $220 | Feb 11, 2026 |
| Barclays | Maintained | Overweight | $210 $225 | Feb 11, 2026 |
| Jefferies | Maintained | Buy | $215 $220 | Feb 11, 2026 |
| Citigroup | Maintained | Neutral | $190 $215 | Feb 10, 2026 |
| Piper Sandler | Maintained | Neutral | $190 $200 | Oct 27, 2025 |
| Barclays | Maintained | Equal-Weight | $190 $195 | Oct 22, 2025 |
| Truist Securities | Maintained | Hold | $195 $205 | Oct 22, 2025 |
| Leerink Partners | Maintained | Outperform | $203 $210 | Oct 21, 2025 |
| Jefferies | Maintained | Buy | $200 $215 | Oct 21, 2025 |
157 filings from 20 insiders · 28 buy / 4 sell over 6m
Officers and directors of DGX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Davis J. E.Director; Officer, CEO and President | Sell | 10.0k | $242.72 | $2.43M | Sep 1, 2026 |
| PREVOZNIK MICHAEL EOfficer, SVP & General Counsel | ExerciseNon-Qualifed Stock Option (right to buy) | 22.7k | $112.17 | $2.54M | Aug 28, 2026 |
| PREVOZNIK MICHAEL EOfficer, SVP & General Counsel | Gift | 1.0k | — | — | Aug 28, 2026 |
| PREVOZNIK MICHAEL EOfficer, SVP & General Counsel | Sell | 430 | $244.51 | $105k | Aug 28, 2026 |
| PREVOZNIK MICHAEL EOfficer, SVP & General Counsel | Sell | 6.2k | $243.63 | $1.52M | Aug 28, 2026 |
| PREVOZNIK MICHAEL EOfficer, SVP & General Counsel | Sell | 16.0k | $242.88 | $3.89M | Aug 28, 2026 |
| PREVOZNIK MICHAEL EOfficer, SVP & General Counsel | Exercise | 22.7k | $112.17 | $2.54M | Aug 28, 2026 |
| DELANEY MARK EOfficer | Sell | 1.6k | $235.18 | $376k | Jul 28, 2026 |
| MAIN TIMOTHY LDirector | Buy | 21 | $206.81 | $4k | Jul 22, 2026 |
| CARTER ROBERT BDirector | Buy | 11 | $206.80 | $2k | Jul 22, 2026 |
| PLEWMAN PATRICKOfficer | Buy | 46 | $206.81 | $10k | Jul 22, 2026 |
| LASSITER WRIGHT IIIDirector | Buy | 6 | $206.81 | $1k | Jul 22, 2026 |
| KUPPUSAMY KARTHIKOfficer | Buy | 37 | $206.81 | $8k | Jul 22, 2026 |
| DELANEY MARK EOfficer | Buy | 34 | $206.81 | $7k | Jul 22, 2026 |
| GREGG VICKY BDirector | Grant | 72 | $206.81 | $15k | Jul 22, 2026 |
| SAMAD SAMER ABDULChief Financial Officer | Grant | 102 | $206.81 | $21k | Jul 22, 2026 |
| KUPPUSAMY KARTHIKOfficer | Exercise | 8.1k | $121.80 | $1.01M | Jun 4, 2026 |
| KUPPUSAMY KARTHIKOfficer | Sell | 8.1k | $200.00 | $1.63M | Jun 4, 2026 |
| MAIN TIMOTHY LDirector | Grant | 1.1k | — | — | May 20, 2026 |
| RING TIMOTHY MDirector | Grant | 1.1k | — | — | May 20, 2026 |
No analyst notes on DGX yet.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 7 | 7 | 0 | 1 | Buy2.47 |
| 1 mo ago | 2 | 7 | 7 | 0 | 1 | Buy2.47 |
| 2 mo ago | 2 | 7 | 7 | 0 | 1 | Buy2.47 |
| 3 mo ago | 2 | 7 | 8 | 0 | 1 | Hold2.50 |